← Oruka Therapeutics, Inc. (ORKA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Oruka Therapeutics, Inc. (ORKA)
Pharmaceutical Preparations · market cap $5.8B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Oruka Therapeutics (ORKA) is a clinical-stage pharmaceutical company with a market cap of ~$5.2B and only 28 employees, focused exclusively on plaque psoriasis. Its pipeline consists of ORKA-001 (induction and maintenance formulations) and ORKA-002, all in Phase 2, with the key readout for ORKA-001 expected around June 2027. The company carries $49.5M in cash, implying roughly 6 months of runway against ~$100M annual R&D spend.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 2 · ORKA-001imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ORKA-001 Induction Dose | Phase 2 | Plaque Psoriasis |
| ORKA-001 | Phase 2 | Plaque Psoriasis |
| ORKA-002 | Phase 2 | Plaque Psoriasis |
Price & technical context
3-month
+1.5%
6-month
+58.3%
12-month
+353.2%
52-wk range
$19.18–$113.08
vs 50-day MA
-11.9%
vs 200-day MA
+32.0%
Realized vol
67.5%
Max drawdown
-77.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ORKA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.